235 related articles for article (PubMed ID: 26823828)
41. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
42. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.
Gnjatic S; Atanackovic D; Jäger E; Matsuo M; Selvakumar A; Altorki NK; Maki RG; Dupont B; Ritter G; Chen YT; Knuth A; Old LJ
Proc Natl Acad Sci U S A; 2003 Jul; 100(15):8862-7. PubMed ID: 12853579
[TBL] [Abstract][Full Text] [Related]
43. Role of a serum-based biomarker panel in the early diagnosis of lung cancer for a cohort of high-risk patients.
Yang DW; Zhang Y; Hong QY; Hu J; Li C; Pan BS; Wang Q; Ding FH; Ou JX; Liu FL; Zhang D; Zhou JB; Song YL; Bai CX
Cancer; 2015 Sep; 121 Suppl 17():3113-21. PubMed ID: 26331818
[TBL] [Abstract][Full Text] [Related]
44. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad antibody responses in humans, a RAYS-based analysis.
Mischo A; Bubel N; Cebon JS; Samaras P; Petrausch U; Stenner-Liewen F; Schaefer NG; Kubuschok B; Renner C; Wadle A
Int J Oncol; 2011 Jul; 39(1):287-94. PubMed ID: 21573493
[TBL] [Abstract][Full Text] [Related]
45. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
[TBL] [Abstract][Full Text] [Related]
46. NY-ESO-1 expression and immunogenicity in prostate cancer patients.
Gati A; Lajmi N; Derouiche A; Marrakchi R; Chebil M; Benammar-Elgaaied A
Tunis Med; 2011 Oct; 89(10):779-83. PubMed ID: 22076902
[TBL] [Abstract][Full Text] [Related]
47. Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.
Milne K; Barnes RO; Girardin A; Mawer MA; Nesslinger NJ; Ng A; Nielsen JS; Sahota R; Tran E; Webb JR; Wong MQ; Wick DA; Wray A; McMurtrie E; Köbel M; Kalloger SE; Gilks CB; Watson PH; Nelson BH
PLoS One; 2008; 3(10):e3409. PubMed ID: 18923710
[TBL] [Abstract][Full Text] [Related]
48. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
49. The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.
Shang XY; Chen HS; Zhang HG; Pang XW; Qiao H; Peng JR; Qin LL; Fei R; Mei MH; Leng XS; Gnjatic S; Ritter G; Simpson AJ; Old LJ; Chen WF
Clin Cancer Res; 2004 Oct; 10(20):6946-55. PubMed ID: 15501973
[TBL] [Abstract][Full Text] [Related]
50. NY-ESO-1 expression and immunogenicity in esophageal cancer.
Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
[TBL] [Abstract][Full Text] [Related]
51. Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.
Sugita M; Geraci M; Gao B; Powell RL; Hirsch FR; Johnson G; Lapadat R; Gabrielson E; Bremnes R; Bunn PA; Franklin WA
Cancer Res; 2002 Jul; 62(14):3971-9. PubMed ID: 12124329
[TBL] [Abstract][Full Text] [Related]
52. Combination of autoantibodies against NY-ESO-1 and viral capsid antigen immunoglobulin A for improved detection of nasopharyngeal carcinoma.
Peng YH; Xu YW; Qiu SQ; Hong CQ; Zhai TT; Li EM; Xu LY
Oncol Lett; 2014 Sep; 8(3):1096-1102. PubMed ID: 25120665
[TBL] [Abstract][Full Text] [Related]
53. Diagnostic and therapeutic relevance of NY-ESO-1 expression in oral squamous cell carcinoma.
Ries J; Mollaoglu N; Vairaktaris E; Neukam FW; Nkenke E
Anticancer Res; 2009 Dec; 29(12):5125-30. PubMed ID: 20044626
[TBL] [Abstract][Full Text] [Related]
54. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.
Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ
Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938
[TBL] [Abstract][Full Text] [Related]
55. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer.
Lam S; Boyle P; Healey GF; Maddison P; Peek L; Murray A; Chapman CJ; Allen J; Wood WC; Sewell HF; Robertson JF
Cancer Prev Res (Phila); 2011 Jul; 4(7):1126-34. PubMed ID: 21733826
[TBL] [Abstract][Full Text] [Related]
56. Immunohystochemical expression of cancer/testis antigens (MAGE-A3/4, NY-ESO-1) in non-small cell lung cancer: the relationship with clinical-pathological features.
Grah J; Samija M; Juretić A; Sarcević B; Sobat H
Coll Antropol; 2008 Sep; 32(3):731-6. PubMed ID: 18982744
[TBL] [Abstract][Full Text] [Related]
57. Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?
Hirose T; Okuda K; Yamaoka T; Ishida K; Kusumoto S; Sugiyama T; Shirai T; Ohnshi T; Ohmori T; Adachi M
Lung Cancer; 2011 Feb; 71(2):224-8. PubMed ID: 20537424
[TBL] [Abstract][Full Text] [Related]
58. Evaluating the diagnostic and prognostic value of serum TuM2-PK, NSE, and ProGRP in small cell lung cancer.
Li L; Zhang Q; Wang Y; Xu C
J Clin Lab Anal; 2023 Apr; 37(7):e24865. PubMed ID: 37088873
[TBL] [Abstract][Full Text] [Related]
59. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H; Isobe M; Kakimi K; Mizote Y; Eikawa S; Sato E; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Yamasaki M; Miyata H; Matsushita H; Udono H; Seto Y; Yamada K; Nishikawa H; Pan L; Venhaus R; Oka M; Doki Y; Nakayama E
J Immunother; 2014; 37(2):84-92. PubMed ID: 24509171
[TBL] [Abstract][Full Text] [Related]
60. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE.
Molina R; Auge JM; Escudero JM; Marrades R; Viñolas N; Carcereny E; Ramirez J; Filella X
Tumour Biol; 2008; 29(6):371-80. PubMed ID: 19060513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
